查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1604650

节肢动物传播的病毒传染病检查市场：按测试类型、最终用户划分 - 2025-2030 年全球预测

Arthropod-borne Viral Infections Testing Market by Test Type (Cultural Tests, Immunoassays, Molecular Tests), End-user (Diagnostic Centers, Hospitals, Research Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

节肢动物病毒传染病检查市场2023年估值为109.9亿美元，预计2024年将达到121.8亿美元，复合年增长率为10.88%，到2030年预计将达到226.6亿美元。

节肢动物传播的病毒传染病检查的范围包括旨在检测透过节肢动物（例如蚊子、蜱虫和跳蚤）传播的病毒感染的诊断程序。这些感染疾病包括兹卡病毒、登革热、基孔肯雅热和西尼罗河病毒。对此类检测的需求源于快速、准确诊断的需要，以促进及时的医疗干预、控制疫情并指导公共卫生措施。最终用途包括公共卫生机构、研究机构和医疗设施，以及实验室、医院和诊断中心的应用。市场成长受到全球旅行增加、都市化、气候变迁以及节肢动物传播疾病意识增强等因素的影响，导致对先进检测方法的需求增加。 PCR 和次世代定序等分子诊断技术的进步带来了潜在的商机。建议包括投资研发，开发具有成本效益、快速且高度准确的测试解决方案，特别是可以使偏远和资源贫乏地区的访问民主化的照护现场诊断。

主要市场统计
基准年[2023] 109.9亿美元
预测年份 [2024] 121.8亿美元
预测年份 [2030] 226.6亿美元
复合年增长率（%） 10.88%

影响市场的挑战包括监管障碍、先进测试技术的高成本以及新兴市场地区基础设施有限。此外，抗药性病毒株的出现和盛行率的区域差异增加了复杂性。此外，缺乏熟练的专业人员来进行和解释测试也可能会限制市场的成长。整合资料分析和人工智慧的多重测试平台和数位解决方案的创新可以开闢新的研究途径。与政府和非政府组织合作提供资金筹措和支援可以减少进入障碍并扩大影响范围。市场洞察表明，迫切需要共同努力对卫生专业人员和公众进行预防措施教育。该市场本质上是动态的，并且受到节肢动物传播性行为感染的季节性和地理波动的影响。将传统诊断与新技术相结合的积极主动的方法对于抓住成长机会并应对这一市场格局中的挑战至关重要。

市场动态：快速发展的节肢动物传播病毒传染病检查市场的关键市场洞察

节肢动物传播的传染病检查市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 节肢动物传播的病毒感染增加
    • 改进节肢动物传播病毒的诊断方法
    • 关于虫媒病毒感染疾病的政府措施和宣传宣传活动
  • 市场限制因素
    • 节肢动物传播的病毒感染疾病诊断试剂套件发生产品召回
  • 市场机会
    • 扩大基于 ELISA 的诊断测试的接受度
    • 测试方法的技术进步
  • 市场问题
    • 开发用于研发和疫苗开发的虫媒病毒动物模型的困难

波特的五力：驾驭节肢动物传播的病毒传染病检查市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解节肢动物病毒传染病检查市场的外部影响

外部宏观环境因素在塑造节肢动物病毒传染病检查市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解节肢动物传播的病毒传染病检查市场的竞争格局

对节肢动物传播的病毒传染病检查市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：节肢动物传播病毒传染病检查市场供应商的绩效评估

FPNV 定位矩阵是评估节肢动物病毒传染病检查市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：在节肢动物传播的病毒传染病检查市场中製定成功之路

对于希望加强在全球市场的影响力的公司来说，对节肢动物传播的病毒传染病检查市场进行策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 节肢动物传播的病毒感染增加
      • 改善节肢动物传播的病毒诊断
      • 关于虫媒病毒感染的政府措施和宣传宣传活动
    • 抑制因素
      • 节肢动物传播病毒感染疾病诊断试剂套件产品回收案例
    • 机会
      • 基于ELISA的检测诊断的普及
      • 测试方法的技术进步
    • 任务
      • 开发用于研究和疫苗开发的虫媒病毒动物模型的困难
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章节肢动物传播的病毒传染病检查市场：依检测类型

  • 介绍
  • 文化测试
  • 免疫学测试
  • 分子检测

第七章节肢动物传播的病毒传染病检查市场：依最终用户分类

  • 介绍
  • 诊断中心
  • 医院
  • 研究中心

第八章 美洲节肢动物病毒传染病检查市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太节肢动物病毒传染病检查市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲节肢动物病毒传染病检查市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Abnova Corporation
  • ACROBiosystems
  • AdvaCare Pharma
  • ARUP Laboratories
  • Bio Lab Diagnostics（I）Private Limited
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • BIOGENIX INC. PVT. LTD.
  • bioMerieux SA
  • Chembio Diagnostics, Inc.
  • Clongen Laboratories, LLC
  • Coppe Laboratories
  • EIKEN CHEMICAL Co., Ltd.
  • Elabscience BIoTechnology Inc.
  • EUROIMMUN AG by PerkinElmer Inc.
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • InBios International, Inc.
  • J Mitra & Co Ltd
  • Kephera Diagnostics
  • Merck KGaA
  • Quest Diagnostics Incorporated
  • Sonora Quest Laboratories LLC
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4103B31E09C0

The Arthropod-borne Viral Infections Testing Market was valued at USD 10.99 billion in 2023, expected to reach USD 12.18 billion in 2024, and is projected to grow at a CAGR of 10.88%, to USD 22.66 billion by 2030.

The scope of Arthropod-borne Viral Infections Testing encompasses diagnostic procedures aimed at detecting viral infections transmitted through arthropods such as mosquitoes, ticks, and fleas. These infections include Zika virus, dengue fever, chikungunya, West Nile virus, and others. The necessity for such testing arises from the need for rapid and accurate diagnosis to facilitate timely medical interventions, control outbreaks, and guide public health policies. Applications extend to laboratories, hospitals, and diagnostic centers, with end-use spanning public health agencies, research institutes, and healthcare facilities. Market growth is influenced by factors such as the rise in global travel, urbanization, climate change, and increasing awareness about arthropod-borne diseases, leading to higher demand for advanced testing methodologies. Technological advancement in molecular diagnostics, including PCR and next-generation sequencing, presents potential opportunities. Recommendations include investing in R&D for developing cost-effective, rapid, and high-accuracy testing solutions, especially point-of-care diagnostics that could democratize access in remote or under-resourced areas.

KEY MARKET STATISTICS
Base Year [2023] USD 10.99 billion
Estimated Year [2024] USD 12.18 billion
Forecast Year [2030] USD 22.66 billion
CAGR (%) 10.88%

Challenges impacting the market include regulatory hurdles, high costs of advanced testing technology, and limited infrastructure in developing regions. Furthermore, the emergence of drug-resistant virus strains and variable prevalence rates across different geographies add complexity. Limitations in the availability of skilled professionals to perform and interpret tests may also restrain market growth. Innovations in multiplex testing platforms and digital solutions that integrate data analytics and artificial intelligence could open new research avenues. Collaborations with governmental and non-governmental organizations for funding and support can ease entry barriers and expand reach. Market insights suggest an urgent need for concerted efforts in educating healthcare professionals and the general populace regarding preventive measures. The market is inherently dynamic, driven by seasonal and geographical variations in arthropod-borne infections. A proactive approach, combining traditional diagnostic methods with emerging technologies, will be crucial for addressing the challenges while seizing growth opportunities in this market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Arthropod-borne Viral Infections Testing Market

The Arthropod-borne Viral Infections Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing arthropod-borne viral infections
    • Improvements in arthropod-borne viral diagnostics
    • Government initiatives and awareness campaigns regarding arboviral infections
  • Market Restraints
    • Product recall incidences of arthropod-borne viral infections diagnostic kits
  • Market Opportunities
    • Rising acceptance of ELISA-based test diagnostics
    • Technological advancements in testing methods
  • Market Challenges
    • Difficulties in developing arbovirus animal models for research study and vaccine development

Porter's Five Forces: A Strategic Tool for Navigating the Arthropod-borne Viral Infections Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Arthropod-borne Viral Infections Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Arthropod-borne Viral Infections Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Arthropod-borne Viral Infections Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Arthropod-borne Viral Infections Testing Market

A detailed market share analysis in the Arthropod-borne Viral Infections Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Arthropod-borne Viral Infections Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Arthropod-borne Viral Infections Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Arthropod-borne Viral Infections Testing Market

A strategic analysis of the Arthropod-borne Viral Infections Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Arthropod-borne Viral Infections Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, ACROBiosystems, AdvaCare Pharma, ARUP Laboratories, Bio Lab Diagnostics (I) Private Limited, Bio-Rad Laboratories, Inc., Bio-Techne, BIOGENIX INC. PVT. LTD., bioMerieux SA, Chembio Diagnostics, Inc., Clongen Laboratories, LLC, Coppe Laboratories, EIKEN CHEMICAL Co., Ltd., Elabscience Biotechnology Inc., EUROIMMUN AG by PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Hologic, Inc., InBios International, Inc., J Mitra & Co Ltd, Kephera Diagnostics, Merck KGaA, Quest Diagnostics Incorporated, Sonora Quest Laboratories LLC, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Arthropod-borne Viral Infections Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Cultural Tests, Immunoassays, and Molecular Tests.
  • Based on End-user, market is studied across Diagnostic Centers, Hospitals, and Research Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing arthropod-borne viral infections
      • 5.1.1.2. Improvements in arthropod-borne viral diagnostics
      • 5.1.1.3. Government initiatives and awareness campaigns regarding arboviral infections
    • 5.1.2. Restraints
      • 5.1.2.1. Product recall incidences of arthropod-borne viral infections diagnostic kits
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising acceptance of ELISA-based test diagnostics
      • 5.1.3.2. Technological advancements in testing methods
    • 5.1.4. Challenges
      • 5.1.4.1. Difficulties in developing arbovirus animal models for research study and vaccine development
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Arthropod-borne Viral Infections Testing Market, by Test Type

  • 6.1. Introduction
  • 6.2. Cultural Tests
  • 6.3. Immunoassays
  • 6.4. Molecular Tests

7. Arthropod-borne Viral Infections Testing Market, by End-user

  • 7.1. Introduction
  • 7.2. Diagnostic Centers
  • 7.3. Hospitals
  • 7.4. Research Centers

8. Americas Arthropod-borne Viral Infections Testing Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Arthropod-borne Viral Infections Testing Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Arthropod-borne Viral Infections Testing Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abnova Corporation
  • 3. ACROBiosystems
  • 4. AdvaCare Pharma
  • 5. ARUP Laboratories
  • 6. Bio Lab Diagnostics (I) Private Limited
  • 7. Bio-Rad Laboratories, Inc.
  • 8. Bio-Techne
  • 9. BIOGENIX INC. PVT. LTD.
  • 10. bioMerieux SA
  • 11. Chembio Diagnostics, Inc.
  • 12. Clongen Laboratories, LLC
  • 13. Coppe Laboratories
  • 14. EIKEN CHEMICAL Co., Ltd.
  • 15. Elabscience Biotechnology Inc.
  • 16. EUROIMMUN AG by PerkinElmer Inc.
  • 17. F. Hoffmann-La Roche Ltd
  • 18. Hologic, Inc.
  • 19. InBios International, Inc.
  • 20. J Mitra & Co Ltd
  • 21. Kephera Diagnostics
  • 22. Merck KGaA
  • 23. Quest Diagnostics Incorporated
  • 24. Sonora Quest Laboratories LLC
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CULTURAL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2023